ASTRAZENECA PLC — All Filings
1,000 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
11-K
144
20-F
20-F/A
25
25-NSE
3
3/A
4
424B2
424B3
424B5
425
6-K
6-K/A
8-A12B
8-A12B/A
CERT
CERTNYS
CORRESP
CT ORDER
DFAN14A
EFFECT
F-3
F-3ASR
F-4
F-4/A
F-6
F-6 POS
F-6EF
FWP
IRANNOTICE
NO ACT
S-1
S-8
S-8 POS
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SC TO-C
SC TO-T
SC TO-T/A
SCHEDULE 13D/A
SCHEDULE 13G/A
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 6-K | ASTRAZENECA COMPLETES ACQUISITION OF ICOSAVAX | 0001654954-24-001914 | Feb 20, 2024 | — |
| 6-K | FORM 6-K | 0001104659-24-025224 | Feb 20, 2024 | — |
| SC TO-T/A | SC TO-T/A | 0001104659-24-025223 | Feb 20, 2024 | — |
| 6-K | ANNUAL FINANCIAL REPORT | 0001654954-24-001937 | Feb 20, 2024 | — |
| 6-K | FORM 6-K | 0001104659-24-025540 | Feb 20, 2024 | — |
| 20-F | FORM 20-F | 0001104659-24-025553 | Feb 20, 2024 | Dec 31, 2023 |
| IRANNOTICE | IRANNOTICE | 0001104659-24-025568 | Feb 20, 2024 | — |
| 6-K | TAGRISSO IMPROVED PFS IN STAGE III LUNG CANCER | 0001654954-24-001899 | Feb 20, 2024 | Feb 19, 2024 |
| 6-K | FDA ACCEPTS DATO-DXD BLA FOR NONSQUAMOUS NSCLC | 0001654954-24-001903 | Feb 20, 2024 | — |
| 6-K | TAGRISSO PLUS CHEMO APPROVED IN US FOR LUNG CANCER | 0001654954-24-001908 | Feb 20, 2024 | — |
| S-8 | FORM S-8 | 0001104659-24-025610 | Feb 20, 2024 | — |
| SC TO-T/A | SC TO-T/A | 0001104659-24-024104 | Feb 15, 2024 | — |
| SC 13G/A | SC 13G/A | 0001104659-24-013882 | Feb 12, 2024 | — |
| 6-K | FINAL RESULTS | 0001654954-24-001467 | Feb 8, 2024 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-24-001173 | Feb 1, 2024 | — |
| SC 13G/A | — | 0001086364-24-002650 | Jan 24, 2024 | — |
| 6-K | FORM 6-K | 0001104659-24-005026 | Jan 19, 2024 | — |
| SC TO-T/A | SC TO-T/A | 0001104659-24-005033 | Jan 19, 2024 | — |
| SC TO-T/A | SC TO-T/A | 0001104659-24-003090 | Jan 11, 2024 | — |
| CORRESP | — | 0001104659-24-003086 | Jan 10, 2024 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-24-000032 | Jan 2, 2024 | — |
| 6-K | ASTRAZENECA ACQUIRES GRACELL | 0001654954-23-015982 | Dec 27, 2023 | — |
| SC TO-T | SC TO-T | 0001104659-23-129493 | Dec 27, 2023 | — |
| 6-K | FORM 6-K | 0001104659-23-129281 | Dec 26, 2023 | — |
| 6-K | WAINUA (EPLONTERSEN) GRANTED FIRST US FDA APPROVAL | 0001654954-23-015901 | Dec 22, 2023 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-23-015521 | Dec 14, 2023 | — |
| SC TO-C | SC TO-C | 0001104659-23-125421 | Dec 12, 2023 | — |
| 6-K | ASTRAZENECA TO ACQUIRE ICOSAVAX | 0001654954-23-015390 | Dec 12, 2023 | — |
| 6-K | FORM 6-K | 0001104659-23-125420 | Dec 12, 2023 | — |
| 6-K | BLOCK LISTING INTERIM REVIEW | 0001654954-23-015044 | Dec 1, 2023 | — |
| 6-K | DISCONTINUATION OF TWO CRYSTALIZE EVIDENCE TRIALS | 0001654954-23-015010 | Dec 1, 2023 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-23-015043 | Dec 1, 2023 | — |
| 6-K | DIRECTOR/PDMR SHAREHOLDING | 0001654954-23-014734 | Nov 24, 2023 | — |
| 6-K | TRUQAP APPROVED IN US FOR HR+ BREAST CANCER | 0001654954-23-014510 | Nov 17, 2023 | — |
| SC 13D/A | SC 13D/A | 0001104659-23-118991 | Nov 16, 2023 | — |
| 6-K | UPDATE ON PACIFIC-2 PHASE III TRIAL FOR IMFINZI | 0001654954-23-014199 | Nov 14, 2023 | — |
| 25-NSE | — | 0001354457-23-000837 | Nov 14, 2023 | — |
| 144 | — | 0001104659-23-116769 | Nov 13, 2023 | — |
| SC 13D | SC 13D | 0001104659-23-116366 | Nov 9, 2023 | — |
| 6-K | DIRECTOR DECLARATION | 0001654954-23-013975 | Nov 9, 2023 | — |
| 6-K | IMFINZI COMBINATION IMPROVES PFS IN LIVER CANCER | 0001654954-23-013973 | Nov 9, 2023 | — |
| 6-K | AGREEMENT WITH ECCOGENE FOR CLINICAL STAGE GLP-1RA | 0001654954-23-013971 | Nov 9, 2023 | — |
| 6-K | 9M AND Q3 2023 RESULTS | 0001654954-23-013969 | Nov 9, 2023 | Nov 2, 2023 |
| 6-K | ASTRAZENECA CELL & GENE THERAPY DEAL W/ CELLECTIS | 0001654954-23-013630 | Nov 1, 2023 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-23-013666 | Nov 1, 2023 | — |
| 6-K | ASTRAZENECA SETTLES NEXIUM LIABILITY LITIGATIONS | 0001654954-23-012523 | Oct 3, 2023 | — |
| 6-K | TOTAL VOTING RIGHTS | 0001654954-23-012469 | Oct 2, 2023 | — |
| 6-K | DATO-DXD IMPROVED PFS IN BREAST CANCER | 0001654954-23-012206 | Sep 25, 2023 | Sep 22, 2023 |
| 6-K | ALEXION COMPLETES PFIZER GENE THERAPY AGREEMENT | 0001654954-23-012050 | Sep 20, 2023 | — |
| 6-K | ENHERTU RECOMMENDED IN EU FOR HER2-MUTANT NSCLC | 0001654954-23-011919 | Sep 15, 2023 | — |